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Abstract
The focus of this chapter is to review the most recent advances in the diagnosis 
and treatment of contact-lens-related infectious keratitis, the most sight-threaten-
ing complication of contact lens wear. In the last decades, contact lenses technology 
has confronted several challenges, including the need for safer and more comfort-
able polymer materials. The development of high coefficient oxygen permeability 
(Dkt) and low-water content disposable contact lens translated into a significant 
improvement in ocular discomfort related to dry eye and allergic reactions, decreas-
ing biofilm build-up on the external surface of the lens. Additionally, the emergence 
and boom-effect of corneal refractive surgery have also driven the development 
of better contact lens manufacturing. Despite these substantial technological 
advances, contact lens users continue to be at risk for developing corneal infections. 
We describe recent epidemiologic data, and advances in understanding the complex 
pathogenesis of the disease, including the clinical characteristics of the infectious 
process produced by bacteria, fungi, and protozoans. Finally, the recent develop-
ment of diagnostic techniques and therapeutic regimens are discussed.
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1. Introduction
Contact lenses are a useful tool for correcting refractive errors; over 125 million 
people wear them worldwide [1]. The widespread use of contact lenses is associated 
with a variable range of complications up to 39–60.99% of contact lens wearers. 
Complications range from mild superficial punctate keratitis to vision-threatening 
conditions such as contact-lens-related infectious keratitis. Infectious keratitis is 
a potentially blinding condition, and it rarely occurs in healthy eyes; it comprises 
bacterial, fungal, and Acanthamoeba keratitis. Contact lens wear is, in fact, the 
predisposing factor in up to 50.3% for infectious keratitis [2–4]. Contact lens wear 
is the most critical risk factor for microbial keratitis in developed countries and the 
second one in developing countries after trauma [5–8]. Despite different contact 
lens materials and wearing modalities, infectious keratitis continues to be a sight-
threatening condition in contact lens wearers, with a rate of visual loss of up to 
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28.6% [3, 9]. The annual incidence rate for contact lens-related microbial keratitis 
is 2/10 000 for rigid contact lens users, 2.2–4.1/10 000 for those who use daily-wear 
soft contact lens, 13.3–20.9/10 000 for extended wear soft contact lens users, and 
52/10 000 for patients who wear therapeutic contact lenses [10].
2. Definition
A classical definition of contact lens-associated infectious keratitis (CLAIK) 
includes a corneal epithelial defect or ulcer, accompanied by a stromal infiltrate, 
requiring corneal scraping and culturing [11]. However, corneal cultures are not 
readily available for all practitioners, suggesting a purely clinical definition [11]. 
Stapleton et al. proposed the following definition: a corneal infiltrate with an over-
lying epithelial defect and one or more of the following: lesions within the 4 mm of 
the central cornea, anterior chamber reaction, and pain [12].
3. Epidemiology
The annual incidence of CLAIK per 10 000 wearers ranges from 0.4–4.0 for 
rigid gas permeable (RGP) contact lenses, 2.2–4.5 for daily use of soft contact 
lenses, and 9.3–20.9 for overnight soft contact lenses wear [11]. Hence, daily wear 
of RGP contact lenses continues to have the lowest infectious keratitis rates [12]; 
however, the incidence of associated microbial keratitis remains unchanged despite 
the development of new contact lens materials [13].
Orthokeratology (ortho-K) for myopia prevention and cosmetic and decorative 
lenses have recently gained popularity among young wearers. On the one hand, 
ortho-K patients are closely monitored during treatment by their practitioners; con-
versely, cosmetic contact lens wear (color or party) lacks care education and profes-
sional supervision. There are reports of microbial keratitis in both wear modalities 
[14, 15]. In the case of cosmetic lens wear not dispensed by eye care professionals, a 
report shows an increased risk of infectious keratitis by a factor of 12.3 (OR 95%-
CI = 4.8–31.5 Furthermore, lack of lens care education in the same study increased 
the risk of infectious keratitis by 26.5 times (OR 95%-CI = 10.0–70.2) [16].
4. Etiology
CLAIK is mainly attributed to bacterial pathogens with up to 90% of the cases 
(Table 1). Moreover, although fungal and protozoal infections are infrequent, 
they are more severe [24]. The most common bacterial agent involved in CLAIK 
is Pseudomonas aeruginosa, according to several reports (Figure 1A and B). 
Gram-negative bacteria are more frequently isolated in tropical climates. Gram-
positive bacteria are more commonly identified in regions with temperate climates 
like Australia and France [2, 3, 11]. Such bacteria include coagulase-negative 
Staphylococcus (including Staphylococcus epidermidis), Staphylococcus aureus, and 
Streptococcus pneumoniae. S. aureus is associated with more severe disease and recur-
rent infections [25].
On the other hand, keratitis caused by Acanthamoeba and fungi has increased 
in the past few years [26]. In 2006, an outbreak of CLAIK caused by Fusarium was 
first reported in Singapore [27], followed by multiple reports in the United States 
[28–30]; these outbreaks were directly linked to a particular contact lens solu-
tion formulation reported a decreased antifungal activity [31]. In the same year, 
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outbreaks of Acanthamoeba keratitis were also reported and partly associated with 
another contact lens solution [32].
It is noteworthy to mention the occurrence of CLAIK associated with multiple 
microorganisms. A retrospective analysis of CLAIK, performed by Karaca et al., 
demonstrated that 20% (12 cases) were mixed infections. All of them were mixed 
bacterium-bacterium infections. P. aeruginosa was involved in eight cases [33]. 
Regarding mixed fungi-bacterial infections, Ahn et al. reported a prevalence of 
4.4% (33/757). Ocular trauma (45.5%) and diabetes mellitus (18.2%) were the 
most frequent associated risk factors for mixed bacterial and fungal keratitis, and 
Fusarium spp. and Staphylococcus spp. were the most frequent fungi and bacteria 
isolated, respectively [34].
5. Risk factors
Among the many different risk factors predisposing to CLAIK, overnight wear 
and poor hygiene are the two most frequent ones, accounting for 43% and 33% 
Figure 1. 
A. The left cornea of a patient with a five day-history of red-eye, discharge, and pain after wearing disposable 
contact lenses overnight. Conjunctival chemosis and ciliary injection are present; a dense stromal infiltrate, 
2 mm hypopyon, and a shallow anterior chamber are observed. B. Fluorescein staining shows an extensive 
overlying epithelial defect. The smear staining revealed a Gram-negative rod, and the culture confirmed the 
diagnosis of Pseudomonas aeruginosa.
Microorganism Frequency (%)
Pseudomonas aeruginosa 6–55.55% [3, 17–22]
Other coagulase-negative Staphylococcus spp. 8–17.64% [20–22]
Serratia marcescens 2–17.1% [3, 17–22]
Staphylococcus aureus 2–12.5% [3, 19–22]
Acanthamoeba spp. 1.96–12.5% [3, 19, 21]
Fusarium spp. 2–12.5% [19, 21, 22]
Propionibacterium acnes 11.76% [21]
Mycobacterium chelonae 6.4% [23]
Streptococcus spp. 3.92–5.9% [20, 21]
Nocardia spp. 1–1.96% [21, 22]
Klebsiella spp. 0–1% [22]
Table 1. 
Prevalence of causal microorganisms of contact lens-associated infectious keratitis.
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of the cases, respectively [35]. Regarding corneal infection in overnight wear, the 
risk is higher with increased extended wear and inexperienced patients [36, 37]. 
Interestingly, in severe keratitis, mishandling of the contact lens case (poor hygiene 
and lack of replacement) accounts for 63% of the population-attributed risk for 
bacterial and fungal infection. Moreover, swimming with contact lenses on and 
traveling are also risk factors for infection. The former for Acanthamoeba keratitis, 
and the latter related to routine wearing changes [3, 38].
Other risk factors of infectious keratitis in contact lens wearers include being 
a male, probably related to poor compliance and reluctance to seek regular care 
attention [39]. Genetic susceptibility related to small mutations of defensins, 
interleukins, and other inflammatory mediators seems to play a role in CLAIK 
(Table 2) [43].
6. Pathogenesis
The primary vector for bacterial transmission in CLAIK is the contact lens 
through various contaminants, including the eyelids, hands, storage case, cosmet-
ics, and contaminated water or lens solutions [44, 45]. Contact lenses wear alone 
alters the normal physiology of the cornea. To a greater or lesser extent, the local 
hypoxia induced by contact lenses causes a decreased epithelial metabolic rate, 
resulting in epithelial thinning, loss of tight cell junctions, and hemidesmosomes, 
Risk factors Highest risk Lowest risk
Modifiable
Wear schedule Overnight use Daily wear only
Days of weekly use 6–7 days < 2 days
Hand washing before cleaning Not always Always
Contact lens type Daily disposable Rigid lenses [36]
Current smoker Yes No
Case hygiene/replace time Poor Excellent
Purchase of contact lens Internet/mail order Optometrist [12]
Showering with lenses Yes No [40]
Water exposure1 Yes2 No [41]
Ocular surface and systemic diseases Presence absence [42]
Non-modifiable
Gender Male Female
Age < 49 years > 50 years [36]
Socioeconomic status3 High [12] Low [3]
Caucasian race1 Yes No [41]
Previous ocular trauma Presence Absence [42]
1Especially related to Acanthamoeba keratitis.
2High risk when exposure to ocean/sea/river/lake water and highest risk when swimming in public or private pool 
and hot tub.
3Low socioeconomic status is associated with higher risk of Acanthamoeba keratitis.
Table 2. 
Modifiable and non-modifiable risk factors associated with contact lens-associated infectious keratitis.
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which lead to epithelial abrasions predisposing to opportunistic infections. Other 
corneal hypoxic effects include vascularization and hypoesthesia.
The understanding of CLAIK pathogenesis has changed over time as contact 
lens materials evolved. Contact lens wear increased in popularity when soft 
hydrogel contact lenses were introduced, given a higher comfort for the wearer 
[46]. However, their intrinsic low-oxygen transmissibility was demonstrated to 
be problematic. It is well-known that lower oxygen transmissibility is related to a 
higher rate of bacterial binding to the corneal surface; hypoxic conditions in human 
corneas increase wild-type cystic fibrosis transmembrane conductance regulator 
(CFTR) expression, which is the cellular receptor for Pseudomonas aeruginosa. 
Hence a lower bacterial load can induce infectious keratitis and inflammatory 
responses in this type of contact lenses [47]. Previous reports show that decreasing 
oxygen permeability of contact lenses is associated with increased desquamation of 
superficial epithelial cells of the cornea [48–50]. These observations led to develop-
ment and innovation in contact lens materials to address the problem of hypoxia, 
which led to the advent of highly oxygen-transmissible, soft silicone hydrogel con-
tact lenses. With the introduction of silicone hydrogel soft contact lenses, a decrease 
in infectious keratitis cases was anticipated; this was hypothesized because of their 
increased oxygen permeability and decreased bacterial binding [50]. However, no 
difference in the incidence of infectious keratitis was observed; clinical character-
istics, pathogens, and rate of vision loss also remained unchanged despite the new 
contact lens material [1].
Because solving the hypoxia mechanism did not result in a reduced incidence 
rate of microbial keratitis, other alternative pathogenic mechanisms are suggested 
for corneal infection, including inadequate tear exchange. Deficient tear exchange 
leads to the entrapment of debris and microbes on the posterior surface of contact 
lenses and hinders the natural antimicrobial functions of the tear film. In fact, there 
is a reduction in the antimicrobial activity of the tear film on the posterior surface 
of silicone hydrogel soft contact lenses after 8 hours of wearing them [51]. This 
mechanism could explain why soft contact lenses are associated with a higher risk 
of infectious keratitis than rigid gas permeable lenses, given the inadequate tear 
exchange in the former [52, 53].
Microbes responsible for infectious keratitis may come from the lid margins, the 
wearers’ fingers upon contact lens insertion, or removal, directly from the contact 
lens or indirectly from the storage case or the lens care solution [54]. Contact lens 
case contamination has been reported in up to 80% of contact lens wearers, despite 
adequate compliance with care regimens [55, 56]. The formation of bacterial biofilm 
on the contact lens surface and storage cases has been previously reported, and it 
may also play a role in the pathogenesis of microbial keratitis [56]. Bacterial cells 
within a biofilm show increased resistance to antimicrobial agents [57]. Moreover, 
multiple biguanide-based contact lens solutions have no effect against biofilms 
of Serratia marcescens, Staphylococcus aureus, and Pseudomonas aeruginosa formed 
in silicone hydrogel contact lenses [58]. Also, outbreaks of keratitis caused by 
Acanthamoeba and Fusarium spp have been linked to specific contact lens solutions 
[26, 27, 32].
Animal models have also been used to improve understanding CLAIK. In 
mouse and guinea pig models, a corneal erosion must occur to produce infectious 
keratitis; animals with non-scratched corneas only show non-infectious inflamma-
tory responses [59]. This has led to the hypothesis that a corneal defect or erosion 
is a prerequisite for CLAIK to occur and not microbial contamination alone [60]. 
Corneal erosions are known complications in contact lens wearers, especially on 
extended wear schedules [61, 62].
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Several risk factors have been associated with microbial keratitis. The most consistent 
factor is overnight wear, which increases the risk for microbial keratitis by 10 to 15 times 
compared to daily wear, irrespective of lens type [9, 12, 50, 63–65]. The extended wear 
risk of infectious keratitis also increases by 9 times with aphakia correction in elderly 
patients; 12 times greater in patients misusing daily-wear lenses for overnight wear. 
Other risk factors include contact lens case hygiene, inadequate or lack of handwashing, 
infrequent case replacement, and smoking; wearing contact lenses while swimming or 
showering also increases the risk [27, 17, 66–71]. Contact lens wearers who live or travel 
to tropical locations also have a higher risk for microbial keratitis [18]. According to the 
lens type, the risk for microbial keratitis is as follows: daily disposable < rigid gas perme-
able < daily wear of soft contact lens < extended wear of soft contact lens [3, 35, 72].
Furthermore, contact lens wear results in a decrease in basal cell proliferation 
on the cornea and vertical migration of differentiated cells to the surface of the 
epithelium, and an abnormal accumulation of older epithelial cells [73, 74].
The pathogenesis of CLAIK is complex and involves intrinsic lens properties, 
including lens material and oxygen transmissibility and environmental variables such 
as bacterial contamination; user behavior, such as schedule wear and poor hygiene 
coupled with the alteration of normal corneal physiology, loss of epithelial adherence 
mechanisms and corneal erosions, lead to the development of microbial keratitis [12]. 
In summary, microbial contamination of the lens is followed by microbial adhesion to 
the corneal epithelium; then microtrauma or erosion to the epithelium occurs, result-
ing in the microbial invasion of the corneal stroma (Figure 2) [75].
7. Diagnosis
Proper diagnosis of CLAIK is based on a complete ocular history of contact 
lens wear, patient’s symptoms, a complete ophthalmological examination, corneal 
scrape, and culture, including the removed contact lens, the case, and solution [66].
7.1 Symptoms and signs
Symptoms common to microbial keratitis include a rapid onset of ocular pain, 
red eye, tearing, foreign body sensation, conjunctival mucopurulent discharge, and 
Figure 2. 
Flow chart showing the relationship between the risk factors and the main events involved in the pathogenesis 
and development of contact lens-associated infectious keratitis.
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photophobia with a variable degree of vision loss. These symptoms are be accompa-
nied by prominent signs including, eyelid swelling, ciliary injection, conjunctival 
chemosis, a corneal epithelial defect or ulceration, stromal inflammatory/microbial 
infiltrate, edema, endothelial keratic precipitates (KPs), and anterior chamber reac-
tion (inflammatory cells, flare, fibrin, plasmoid bodies, hypopyon) [11, 76–78].
There are clinical features that may guide the clinician to a possible etiologi-
cal agent. Bacterial keratitis is characterized by a round, or oval epithelial defect 
with an underlying stromal infiltrate and anterior chamber reaction or hypopyon 
(Figure 3A–C) [66].
The classical findings in Acanthamoeba keratitis are severe pain that is dispro-
portionate to the clinical signs, ring-shaped corneal infiltrates, and radial perineuri-
tis [69, 75]. Fungal keratitis may present with a grayish, deep infiltrate with feathery 
borders and satellite lesions or an endothelial plaque and usually has a more insidi-
ous course [27, 66, 69]. However, these clinical findings are often misleading; in 
fact, cornea specialists distinguish correctly bacterial from fungal keratitis only 
66% of the time in a photographic survey [79]. Thus, corneal scrapings and cultures 
remain the gold standard for microbial identification and the only method for 
determining antibiotic sensitivity [80].
7.2 Smear staining and culture
Corneal scrapings are obtained in the office under the slit lamp. A topical 
anesthetic agent is instilled, ideally proparacaine hydrochloride 0.5% or a preser-
vative-free anesthetic [81]. The corneal material is obtained with a sterile platinum 
spatula, blade, forceps, or a calcium alginate swab moistened in thioglycolate 
broth. The smear stains helpful in identifying the causative organism are Gram 
stain, Giemsa stain, and Acridine orange are the most frequently used for detect-
ing bacteria. The Gram stain permits identification of gram-positive and -negative 
coccus and rods, which is essential to choose the initial antibiotic type before the 
antibiogram and sensitivity profile of the microorganism in question is available. 
For example, cephalosporins are more appropriate for gram-positive and aminogly-
cosides for gram-negative bacteria [82].
In case of presumptive fungal infection, special stains like potassium hydroxide 
(KOH) and calcofluor white (CFW) are more reliable to initiate antifungal therapy 
than Gram staining is for bacterial infection (Figure 4A and B) [82, 83].
Figure 3. 
53 years-old diabetic female using a one-month schedule silicone hydrogel disposable soft contact lenses in 
an overnight extended wear mode. The patient had been treated with 0.3% ciprofloxacin and prednisolone 
acetate 1% for one week. One day after stopping medications, a scrape and culture confirmed Staphylococcus 
spp. infection A. Left cornea showing three round dense stromal infiltrates with moderate stromal edema and 
Descemet folds. B. Positive fluorescein staining (>80% lesion surface) demarcating extensive corneal ulceration 
in all lesions. C. Three weeks on intense topical regime of 0.5% moxifloxacin and fortified vancomycin (50 mg/
ml), the ulcers resolved.
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Mycobacterial or Nocardia infection will require the acid-fast or modified  
Ziehl-Neelsen (1% H2SO4, cold) staining (Table 3).
According to the American Academy of Ophthalmology Bacterial Keratitis 
Preferred Practice Pattern, cultures and smears should be obtained in cases of 
suspected microbial keratitis in the following conditions:
• the presence of a large, central infiltrate and/or accompanied with 
 stromal melting
• chronic or unresponsive infection despite broad-spectrum antibiotic therapy
• atypical clinical findings suggestive of fungal, protozoal, or mycobacte-
rial agents
• multifocal infiltrates or a history of corneal surgery [82].
Corneal scrapings should be directly inoculated into the culture media at room 
temperature and immediately taken to the laboratory for further processing. If 
culture media are not readily available, scrapings should be inoculated into transport 
media, including brain-heart infusion media and amies medium with charcoal. Both 
transport media may be used for aerobic and facultative anaerobic bacteria and, 
the latter, also for fungi [82]. Standard culture media include blood agar, choco-
late agar, Sabouraud dextrose agar, thioglycolate broth, and mannitol salt agar. If 
Acanthamoeba is the suspected pathogen, a non-nutrient agar with Escherichia coli 
overlay must be used (Table 4) [82, 85]. In addition to culturing corneal scrapings, 
cultures of the contact lens and case can also yield positive results. Corneal scrapings 
Figure 4. 
A. Potassium hydroxide (KOH) preparation of a corneal smear from a fungal CLAIK patient, showing septate, 
branched, hyaline hyphae characteristic of filamentous fungus. B. Sabouraud dextrose agar (SDA) plate 
showing white, cottony colonies consistent with Fusarium solani.
Staining technique Visualized microorganisms
Gram Bacteria, fungi and Acanthamoeba
Giemsa Bacteria, fungi and Acanthamoeba
Potassium hydroxide (KOH) Fungi
Acridine orange Bacteria, fungi and Acanthamoeba
Calcofluor white (CFW) Fungi and Acanthamoeba
Acid fast (modified Ziehl-Neelsen) Mycobacteria and Nocardia [82, 84]
Table 3. 
Most used microorganism identification staining techniques for the diagnostic confirmation of contact  
lens-associated infectious keratitis.
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culture provides positive results in 34–44% cases [67, 86–88], while cultures of con-
tact lenses are positive in 67–92%, and 80–85% for contact lens cases [66]. Studies 
have found an association between cultures of corneal scrapings and of contact 
lenses, with a concordance of up to 84% [67, 89]. Therefore, contact lens culture may 
guide in the identification of the causative organism in cases in which the corneal 
scraping culture is negative; however, contact lens cultures do not replace corneal 
cultures as the gold standard for the etiologic diagnosis of microbial keratitis [67].
7.3 Tissue biopsy
A corneal biopsy may be performed if there is an inadequate response to 
treatment or if cultures are repeatedly negative, particularly for suspicious 
Acanthamoeba keratitis (Figure 5A–C). It can be performed at the slit-lamp or in 
the operating room using topical anesthesia and a small 2 or 3-mm dermatologic 
trephine punch; the tissue obtained is then bisected and sent for culture and 
histopathologic analysis. A section of the corneal specimen is homogenized with 
trypticase soy broth and cultured on conventional blood and chocolate agar, 
anaerobic media, Sabouraud agar, and thioglycolate broth; in specific cases, 
the corneal specimen may also be plated on a non-nutrient agar with E. coli or 
Lowenstein Jensen media. The specimen section that is sent for histopathologic 
analysis may be processed with standard stains for bacteria, fungi, acid-fast-bacilli, 
and Acanthamoeba such as Gram and Giemsa stain, potassium hydroxide, calcofluor 
white and, Ziehl-Neelsen [90]. Several considerations should be taken into account 
to maximize the diagnostic yield of a corneal biopsy [90–92]:
• To obtain the tissue specimen, topical antibiotics must be suspended at least 
24–48 hours before the procedure [90]. Also, appropriate planning and con-
sultation with the microbiologist and pathologist is recommended (i.e., need 
for special stains for fastidious organisms, appropriate fixatives if electron 
microscopy is required) [91].
Standard media Isolates
Blood agar Aerobic, anaerobic, and facultative anaerobic bacteria. Pseudomonas 
aeruginosa, Staphylococcus aureus, Staphylococcus epidermidis, Streptococcus 
pneumoniae Saprophytic fungi and Nocardia.
Chocolate agar Aerobic, anaerobic, and facultative anaerobic bacteria. Ideal for isolation 
Haemophilus influenzae, Neisseria gonorrhoeae, and Moraxella.
Sabouraud dextrose agar Fungi and Nocardia
Mannitol-salt agar Staphylococcus spp.
Thioglycolate broth Aerobic and anaerobic bacteria
Supplemental media Isolates
CDC anaerobe blood agar Propionibacterium acnes, Peptostreptococcus spp.




Brain-heart infusion broth Filamentous fungi and yeasts. Aerobic and facultative anaerobic bacteria.
Amies medium without 
charcoal
Aerobic and facultative anaerobic bacteria. Fungi [66, 82, 84, 85]
Table 4. 
Respective culture media type used for microorganism isolation in contact lens-associated infectious keratitis.
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• The biopsy must be performed under appropriate magnification at either the 
operating room or under the slit lamp, with free lamellar dissection using a 
diamond-sharp blade, set at 0.2 to 0.3 mm depth, or a 3 to 5 mm diameter 
trephine (skin biopsy punches), cutting to approximately 0.2 to 0.3 mm depth 
to avoid corneal perforation [92]. After trephination, the base of the tissue 
block must be gently pulled upward and sideways with a Colibri 0.12 mm tooth 
forceps to cut it off with a sharp knife (i.e., Grieshaber knife, Beaver blade 
No.66) or a Vannas scissors, completing the lamellar keratectomy [92].
• The tissue biopsy must include a leading edge of the infiltrate or ulcer, including 
an uninvolved tissue margin [91].
• The tissue sample’s processing technique (i.e., electron and light microscopy 
histopathologic analysis, immunofluorescence, or histochemistry) depends on 
the clinical features and the amount of tissue available. For small specimens 
(<3 mm), it is suggested to use only the technique potentially yielding the best 
result, which must be selected based on a clinical suspicion [91].
• If a large sample is obtained, the specimen is divided under sterile technique 
with a sharp #11 or a 15° knife. Each portion is placed in the appropriate  
fixative [92].
• With a cotton-tipped applicator or a moistened cellulose (Weck-cel) sponge, 
swab the base of the keratectomy and streak the culture material on plates 
containing transport media [92].
7.4 Molecular biology techniques
The most common approach to diagnose CLAIK is to culture microorganisms 
from corneal scrapings. However, more than 99% of the biosphere’s microbes are 
Figure 5. 
Left cornea from a hardware store worker with keratoconus fitted with RGP contact lenses used to wash his face 
with stagnant water in an open tank deposit. A. Dense ring infiltrate with multiple stromal satellite nummular 
lesions and anterior chamber reaction. B. A 3 mm diameter corneal biopsy stained with H&E (mag. 40x), 
showing multiple Acanthamoeba cysts in the corneal stroma. C. Modified Giemsa stain from the same biopsy 
piece enhancing the presence of multiple Acanthamoeba cysts.
11
Contact Lens-Associated Infectious Keratitis: Update on Diagnosis and Therapy
DOI: http://dx.doi.org/10.5772/intechopen.100261
not cultivable using standard laboratory culture techniques [93]. Furthermore, 
identifying slow-growing bacteria (e.g., atypical mycobacteria) or fungi with 
atypical phenotypes is tedious and time-consuming [94]. The advent of molecular 
culture-independent high-throughput sequencing approaches has allowed further 
identification and characterization of microorganisms that cause CLAIK [95].
7.4.1 Polymerase chain reaction (PCR)
PCR is a highly sensitive technique that allows rapid amplification of tiny 
samples of DNA. In the context of infection, it may be used to detect the presence 
of pathogenic DNA of specific microorganisms [96]. The 16S and 18S rRNA are 
the most frequently used marker genes for assessing bacterial and fungal profiles, 
respectively. They are found in all respective microorganisms and have enough 
variation for phylogenetic analysis and sequence conservation for accurate align-
ment [97]. The 16S rRNA gene sequence is 1,550 bp long, and it is composed of nine 
variable regions (V1-V9) interspaced in more conserved regions. By amplifying the 
16S rRNA region with PCR, the background host contamination encountered in 
routing culturing techniques is reduced significantly [98].
Kim et al. compared the detection rate of PCR compared with traditional 
cultures in patients with infectious corneal ulcers [99]. Of 108 samples taken from 
ulcers, 52% were culture-positive and 89% PCR-positive for fungal primers (18S 
rRNA), bacterial primers (16s rRNA), or both. Of note, other nonpathogenic 
organisms (i.e., Ralstonia, Oerksovia, and Leclercia species) were also identified 
in 60% and 52% of the PCR samples and control swabs, respectively. Airborne 
contamination and false-positive results for pan-fungal and pan-bacterial PCR 
constitute a significant limitation of the technique [100]. Moreover, when analyzing 
culture-positive samples, 24% and 6.5% were PCR-negative for bacteria and fungi, 
respectively, suggesting that PCR does not replace traditional culturing. PCR, 
however, accurately distinguishes fungal from bacterial pathogens [99]. In patients 
with suspected Acanthamoeba keratitis, PCR and in-vivo confocal microscopy 
(IVCM, see Section 7.5) are preferred over conventional cultures since the latter has 
a low sensitivity and requires special media and extended incubation periods [101]. 
Goh et al. compared traditional cultures, PCR, and IVCM in the early diagnosis of 
Acanthamoeba keratitis. All methods exhibited a specificity and positive predictive 
value of 100%. However, the diagnostic sensitivities were 100% for IVCM, 71.4% 
for PCR, and 33.3% for traditional cultures. Since IVCM is an expensive device 
and requires an experienced operator, PCR is considered as a valuable adjunct to 
cultures when Acanthamoeba is suspected [101].
7.4.2 Next-generation sequencing (NGS)
NGS encompasses an evolving group of high-throughput sequencing tech-
nologies which allow massive sequencing of nucleic acid. The Sanger (1970s), a 
precursor to NGS, is a first-generation sequencing platform with high accuracy 
when dealing with one bacterium. In fact, the Human Genome Project (2003) was 
completed with the automatization of this technique. Isolated bacterial sequencing 
required multiple reactions with the Sanger platform, and thus, it was complex 
and time consuming [102]. Second-generation platforms (Illumina HiSeq 2500), 
although able to generate high sequence throughput data in a single reaction, 
they only sequenced part of the 16S gene [94, 103, 104]. Current third-generation 
platforms use nanopore sequencing technology directly from clinical samples to 
diagnose bacterial keratitis in real time and with higher accuracy [98].
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Metagenomic NGS (mNGS) is an emerging approach that analyzes microbial, 
and host’s genetic material (DNA and RNA) in samples from patients [105]. mNGS 
may detect all potential pathogens (bacteria, fungi, parasites, and viruses) in a 
clinical or environmental sample and simultaneously interrogate host responses by 
performing billions of reads in a single run [105, 106]. Unfortunately, the untar-
geted nature of this approach most likely results in host-derived reads [102].
Obtaining a rapid, real-time diagnosis of the causative microbe in bacterial 
keratitis will allow the ophthalmologist to initiate prompt and adequate antibiotic 
therapy; thus, improving the visual outcome and reducing antibiotic resistance 
[107]. However, test validation, reproducibility, high costs, among others, are 
significant drawbacks for the routine use of NGS and mNGS in clinical settings. 
Nevertheless, they must be considered in refractory difficult-to-identify cases of 
infection.
7.5 In vivo confocal microscopy (IVCM)
IVCM is a non-invasive imaging technique that allows dissection of the corneal 
architecture at a cellular level, providing real-time images equivalent to those 
obtained from ex-vivo histopathological techniques (tissue biopsy) [108]. It is cur-
rently used to evaluate corneal nerves in healthy eyes and those affected by ectatic 
corneal diseases, neurotrophic keratopathy, corneal dystrophies, ocular surface 
inflammation, contact lens wear, and infectious keratitis [108–110].
The role of IVCM in CLAIK relies on the identification of fungal hyphae 
and Acanthamoeba cysts; bacteria are too small to be visualized by IVCM [111]. 
Chidambaram et al. evaluated the IVCM cellular features in patients with bacte-
rial, fungal, and Acanthamoeba keratitis [112]. A honeycomb-like distribution of 
anterior inflammatory cells in the corneal stroma was distinctive of fungal keratitis. 
Aspergillus and Fusarium ulcers were also associated with stromal dendritiform cells 
and interconnected cell processes with a stellate appearance, respectively. Bacterial 
keratitis was significantly associated with anterior stromal bullae and basal 
dendritiform cells. Normal keratocyte-like morphology was found in most eyes 
with both bacterial and fungal keratitis. Distinguishing features of Acanthamoeba 
included double-walled cysts, bright spots, and clusters after topical steroid use. 
While the keratocyte morphology was altered in 82% of bacterial (82%) and 77% 
of fungal keratitis, it was only abnormal in 39% of Acanthamoeba cases [112].
Although IVCM may be used in culture-negative cases or when the clinical 
diagnosis is unclear, this technique requires an experienced examiner. The rearmost 
since cellular features exhibited in microbial keratitis may be easily confused with 
nerve fibers, activated stromal keratocytes, and Langerhans cells [111]. Moreover, 
its small field of view precludes fair dismissal of Acanthamoeba cysts [113].
8. Differential diagnosis
8.1 Microorganism profile
According to the clinical features of the infectious/inflammatory process seen in 
CLAIK, specific differences, although not compelling, help identify the infectious 
agent involved in the process. For example, Gram-negative bacteria are usually asso-
ciated with a significant anterior chamber reaction and larger ulcers compared to 
Gram-positive ones. Also, Pseudomonas aeruginosa tends to produce larger stromal 
inflammatory infiltrates [2, 40]. A study analyzing the causative microorganism 
involved in CLAIK found moderate positive prediction for Acanthamoeba annular 
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stromal infiltrate at 89% (95% CI = 52–100) and Pseudomonas larger ulcer at 65% 
(95% CI = 43–84) [114]. On the other hand, pseudo-dendrites, epitheliopathy, and 
stromal infiltrate found in Acanthamoeba keratitis may confuse herpetic keratitis 
[115]. Serrated (feathery) ulcer margins with raised and dry texture infiltrate and 
satellite lesions are common features of fungal keratitis [116].
8.2 Infectious versus inflammatory keratitis
One of the first dilemmas confronted by professionals taking care of patients 
wearing contact lenses is to know if the corneal lesion is infectious or inflammatory 
(Figure 6A and B). The difficulty arises because the ocular immune response to for-
eign stimuli, including microbes and their products, foreign bodies, trauma, allergic 
and toxic reactions, is non-specific inflammation, which may be indistinguishable 
from infection in that respect [78, 117, 118]. A study asking ophthalmologists to 
identify sterile from culture-proven CLAIK found good predictability (76%, 95% 
CI = 67–84) with 79 cases classified correctly [114].
Some key clinical features help to differentiate between sterile from infectious 
keratitis. In sterile inflammation, the absence of eyelid edema, no conjunctival 
discharge, peripheral location of the lesion, and minimal or no anterior chamber 
reaction contrast with significant eyelid edema, abundant mucopurulent discharge, 
central/paracentral lesions, and severe reaction and hypopyon formation in infec-
tious keratitis [78].
9. Management
First and foremost, efforts should be focused on the prevention of CLAIK. 
Wearers should be educated on the proper use of contact lenses. They should 
be counseled to avoid overnight wear and exposure to water and be educated on 
appropriate hygiene practices when handling contact lenses and timely contact lens 
replacement [35].
To make the right management decisions, recognizing the risk factors for 
CLAIK, its different clinical infectious patterns, and getting the causal microor-
ganism identification/isolation are critical to obtaining an optimal therapeutic 
response, avoiding sight-threatening severe complications.
Figure 6. 
A. Sterile peripheral inflammatory infiltrate in the right eye due to corneal hypoxia and a tight lens fitting of a 
26-year-old female wearing hydrogel-silicone, one-month schedule disposable contact lenses complaining of red-
eye, foreign body sensation, and tearing from the past three days. B. Fluorescein staining shows a slight epithelial 
defect at the infiltrated site and superficial punctate keratitis.
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9.1 Bacterial keratitis
An early diagnosis and appropriate treatment of infectious keratitis are essential. 
Broad-spectrum topical antibiotics are the first-line therapy for bacterial keratitis 
and should be initiated immediately after cultures are obtained, while waiting for 
the results. Antibiotics should be indicated, taking into consideration the local 
epidemiological data, frequency of specific pathogens, and antibiotic sensitivities 
(Table 5) [82, 119]. Severe keratitis should be treated with an initial loading dose 
every 5 to 15 minutes for the first hour, followed by hourly instillation for 24 to 
48 hours; a topical fortified antibiotic or fluoroquinolone may be used [119].
In a recent meta-analysis, no difference in effectiveness, defined as complete 
corneal re-epithelialization, was observed between the use of commercially avail-
able fourth-generation topical fluoroquinolones and aminoglycoside-cephalosporin 
fortified combinations; there was no difference in time to resolution either. 
However, symptoms of ocular discomfort and toxic conjunctivitis were more 
frequent when using fortified aminoglycoside-cephalosporin combinations (see 
Appendix 1) [119].
Treatment should be tapered according to response to a minimum of four times 
a day, avoiding toxicity from prolonged and unnecessary use of antibiotics [112]. 
If no clinical stabilization or improvement is observed after the first 48 hours of 
treatment, the therapeutic regimen should be modified; culture results and antibi-
otic sensitivity should guide the clinician under these conditions. Good therapeutic 
response features include decreased pain, conjunctival discharge, eyelid edema, 
reduced corneal stromal edema, a decreased anterior chamber response, and signs 
of re-epithelialization. Patients with severe keratitis should be followed daily until 
clinical improvement is observed. Cycloplegic agents may be indicated in cases of 
severe keratitis with significant anterior chamber reaction to prevent the formation 
of irissynechiae and reduce the pain [63].
The use of topical corticosteroids is controversial but may have a role in treat-
ing certain bacterial keratitis to reduce corneal scarring. According to a subgroup 
analysis of the Steroids for Corneal Ulcers Trial (SCUT) in non-Nocardia bacte-
rial keratitis, topical corticosteroids within two to three days of topical antibiotic 
therapy resulted in a one-line improvement in visual acuity compared to placebo 
[120]. However, topical corticosteroid use in Nocardia ulcers was associated with 
larger scars at 12 months, and therefore, it is not recommended for these cases 
[121]. Other well-designed randomized clinical trials are necessary to confirm these 
findings [122] .
9.2 Fungal keratitis
Fungal keratitis is often more aggressive than bacterial keratitis. However, there 
is no consensus on standard treatment, and randomized clinical trials on this subject 
are scarce [122]. Most antifungal medications available for ocular infections have 
significant limitations, including low bioavailability and limited ocular penetration 
in deep-seated lesions (Table 6) [123–125]. Furthermore, antifungal susceptibil-
ity testing has limited availability and is rarely used in ordinary contact lens and 
cornea clinics [126]. The Mycotic Ulcer Treatment Trial I (MUTT I) showed that 
topical natamycin is superior to topical voriconazole treating fungal keratitis in 
general, particularly in those caused by Fusarium [127]. According to the MUTT II 
results, there is no difference in perforation rate or need for therapeutic penetrating 
keratoplasty in fungal ulcers treated with oral voriconazole combined with topical 
antifungal agents compared to oral placebo and equal antifungal topical therapy. 
However, systemic adverse events were more frequent in the oral voriconazole group 
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Cephalosporins: Inhibit bacterial cell wall formation by disrupting the synthesis of peptidoglycans.
Less susceptibility to β-lactamases compared with penicillins.
Cefazolin1 50 mg/mL 100 mg in 0.5 mL Gram-positive cocci
Ceftriaxone 50 mg/mL 100 mg in 0.5 mL Gram-negative cocci2
Ceftazidime 50 mg/mL 100 mg in 0.5 mL Gram-negative cocci / rods
Fluoroquinolones1: Inhibit bacterial DNA gyrase and topoisomerase IV, enzymes required for bacterial DNA 
synthesis.
Ciprofloxacin 3–6 mg/mL Not available Gram-negative cocci / rods
Ofloxacin 3–6 mg/mL Not available Gram-negative cocci / rods
Levofloxacin 5–15 mg/mL Not available + gram-positive cocci
Moxifloxacin 5–6 mg/mL Not available + gram-positive cocci and NTM
Gatifloxacin 5–6 mg/mL Not available
Besifloxacin 5–6 mg/mL Not available
Aminoglycosides: Bind to ribosomal subunits, resulting in defective mRNA translation and inhibition of 
protein biosynthesis.
Gentamicin1 9–14 mg/mL 20 mg in 0.5 mL Gram-negative rods
Tobramycin1 9–14 mg/mL 20 mg in 0.5 mL Gram-negative rods
Amikacin 20–40 mg/mL 20 mg in 0.5 mL NTM / Nocardia
Penicillins: Inhibit bacterial cell wall formation by disrupting the peptidoglycan synthesis.
Penicillin G 100,000 U/mL 1,000,000 U/mL Nonpenicillinase producing gram-
positive organisms
Methicillin 50 mg/mL 200 mg/mL Penicillinase-producing gram-positive 
organisms
Piperacillin 7 mg/mL 200 mg/mL Gram-positives and some gram-
negatives, including Pseudomonas
Glycopeptides: Inhibit cell wall formation of gram-positive bacteria
Vancomycin3 15–50 mg/mL 25 mg in 0.5 mL Gram-positive cocci
Macrolides: Inhibit bacterial protein synthesis by binding to the 50S ribosomal subunit.
Erythromycin4 5 mg/gram Not available Gram-positive bacteria
Clarithromycin 10 mg/mL 20 mg in 0.5 mL NTM
Bacterial folic acid inhibitors: Folic acid, used in DNA synthesis is required by bacteria for growth and 
replication.
Sulfacetamide5 100 mg/mL 20 mg in 0.5 mL Nocardia
TMP-SMX6 16 mg/mL
80 mg/mL
20 mg in 0.5 mL Nocardia
Adapted and modified from Mannis MJ and Holland EJ (Eds.). (2017). Cornea. Elsevier.
NTM, non-tuberculous mycobacteria; TMP-SMX, trimethoprim-sulfamethoxazole.1Also used when no organism or 
multiple types or organisms are identified.
2Systemic therapy is required for suspected gonococcal infection.
3Potent activity against methicillin-resistant Staphylococcus aureus; used for resistant Enterococcus species and 
penicillin allergy. Must not be used as single therapy against bacterial keratitis due to poor gram-negative activity.
4Mostly used in ointment presentation for the management of blepharitis, rarely used in keratitis due to poor corneal 
penetration.
5Active against gram-negative and -positive bacteria; however, used because bacteria become highly resistant during 
therapy.
6Rarely used in bacterial keratitis due to poor corneal penetration when intact epithelium.
Table 5. 
Topical and subconjunctival antibiotics and their indication for microbial keratitis.
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[128]. According to a metanalysis of the available randomized clinical trials, there is 
still limited evidence to support using any particular drug or combination of drugs 
to treat fungal keratitis [129]. In general, topical treatment may include natamycin 
5%, amphotericin-B 0.15% to 0.5 %, or voriconazole 1% or 2% [122].
9.3 Acanthamoeba keratitis
There is no consensus on the standard treatment for Acanthamoeba keratitis. 
Trophozoites are sensitive to a variety of antibiotics, antifungals, antiseptics, and 
antineoplastic agents. In contrast, cysts are highly resistant to a number of these 
drugs [113]. Effective topical treatment for Acanthamoeba cysts may include diami-
dines and biguanides such as propamidine-isethionate 0.1%, hexamidine-diisethi-
onate 0.1%, dibromopropamidine 0.1%, polyhexamethylene-biguanide 0.02%, or 
chlorhexidine 0.02% [130]. A combination therapy of a biguanide and a diamidine 
is often used initially on an hourly schedule for the first 48 hours; treatment is then 
tapered according to the clinical response and potential epithelial toxicity and may 
be continued for several months. The objective is to eradicate Acanthamoeba tropho-
zoites and cysts, with the resolution of the corneal inflammatory response [113].
9.4 Topical corticosteroids in infectious keratitis
The use of topical corticosteroids in infectious keratitis remains controversial 




Polyenes: bind to ergosterol in the fungal cell wall; disruption of cell wall
Dose: initial dose of one drop every 30 minutes with tapering to every 3 to 6 hours
Amphotericin B 0.05%–0.50% First-line therapy for Candida; good activity against 
Aspergillus and Fusarium.
Natamycin 2.5%–5% Aspergillus, Fusarium; moderate for Candida
Azoles: inhibit the synthesis of ergosterol through the cytochrome P-450-dependent enzyme
Dose: undetermined
Clotrimazole 1% Candida, Aspergillus
Econazole 0.02%–2% Fusarium, Aspergillus, Candida
Voriconazole 1%–2% Candida, Aspergillus
Itraconazole 1% Candida, Aspergillus
Fluconazole 0.5%–1% Candida and other yeasts
Ketoconazole 1%–2% Candida and Aspergillus
Echinocandins: block beta-glucan synthesis
Dose: undetermined
Caspofungin 0.5% Candida, Aspergillus
Micafungin 0.1% Candida, Aspergillus
Allylamines: block ergosterol biosynthesis by inhibition of squalene epoxidase
Dose: undetermined
Terbinafine 0.25% Aspergillus, Fusarium and Candida
Adapted and modified from Mannis MJ and Holland EJ (Eds.). (2017). Cornea. Elsevier.
Table 6. 
Topical antifungals formulations for the treatment of mycotic keratitis.
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inflammation, opacification, and neovascularization. Others oppose their use, 
claiming that they might exacerbate microbial replication, delay epithelial heal-
ing, accelerate stromal melting, and increase the risk of perforation [132]. Several 
authors have demonstrated in non-controlled studies that prior corticosteroid use 
in bacterial keratitis significantly increases the risk of antibiotic failure and corneal 
ulceration [132, 133]. A Cochrane review of three small randomized trials found 
no benefit in healing times or visual acuity outcomes with adjuvant corticosteroid 
treatment [134]. The Steroids for Corneal Ulcers Trial (SCUT), the largest ran-
domized controlled trial to date, showed no overall benefit of steroid use in visual 
acuity, scar size, or perforation rate at 3-months follow-up [121]. Of note, steroids 
(prednisolone sodium phosphate 1%) or placebo were started after 48 hours of 
topical 0.5% moxifloxacin. The SCUT also demonstrated that adjuvant corticoste-
roids, compared to placebo, resulted in one-line improvement in visual acuity in 
non-Nocardia ulcers and more extensive scars in Nocardia ulcers at one year [121]. 
In a recent report by the American Academy of Ophthalmology, authors suggest 
using topical corticosteroids after 48 hours of antibiotic therapy in culture-positive 
non-Nocardia bacterial keratitis [122].
Similar results were described by Wouters et al. in eyes with Acanthamoeba kera-
titis [135]. Topical corticosteroid use was associated with a delay in diagnosis (23 
vs. 62 days, p < 0.001), increased disease severity, worst visual outcomes (<20/80, 
p = 0.03), and the need for an urgent corneal transplant [135].
In a recent murine model of Candida albicans, topical 0.1% dexamethasone 
exacerbated fungal keratitis by increasing the aggressivity of the pathogen, reduc-
ing the neutrophil infiltration, and inhibiting the formation of neutrophil extracel-
lular traps [136].
9.5 Corneal collagen crosslinking (CXL)
Corneal CXL is a therapeutic modality consisting of photoactivation of a 
chromophore, riboflavin (vitamin-B2), by ultraviolet (UVA) light at a wavelength 
of 370 nm. This technique is mainly used for stabilizing the corneal curvature and 
vision in patients with keratoconus and ectatic disorders [137, 138]. Studies suggest 
that guanine oxidation of nucleic acids and reactive oxygen species generation by 
activated riboflavin results in nucleic acid destruction with subsequent microbial 
proliferation. In 2013, the term photoactivated chromophore for infectious kerati-
tis-corneal collagen crosslinking (PACK-CXL) emerged [137].
Price et al. performed the first prospective study assessing the efficacy of CXL 
in infectious keratitis [139]. PACK-CXL was deemed more effective for bacterial 
keratitis involving the superficial layers of the corneal stroma [139]. Another 
prospective clinical trial randomized 40 eyes to receive either PACK-CXL in 
addition to antimicrobial therapy or antimicrobial therapy alone [140]. Although 
PACK-CXL did not shorten the corneal healing time compared to the control group, 
it did result in an absent incidence of corneal perforation or recurrence of infection 
(0% vs. 21%) [140]. A recent meta-analysis performed by Ting et al., including four 
randomized-control trials, demonstrates that adjuvant PACK-CXL results in shorter 
mean healing times and quicker resolution of infiltrates when comparing with anti-
microbial treatment alone. Despite the latter, high-quality randomized controlled 
trials are required to establish PACK-CXL’s efficacy in infectious keratitis fully [141].
9.6 Rose bengal photodynamic antimicrobial therapy (RB-PDAT)
RB-PDAT is an emerging therapeutic modality for the management of infectious 
keratitis [142]. It was first introduced by Amescua et al. in 2017 for the management 
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of a patient with multidrug-resistant Fusarium keratoplasticum keratitis [143]. In 
this therapeutic modality, rose bengal, a routinely used dye in ophthalmology, 
is excited with a green light at a wavelength of 500–550 nm to generate reactive 
oxygen species [144]. Rose bengal is a type II photosensitizer that, when activated, 
induces cellular apoptosis by converting triplet oxygen to singlet oxygen [142]. A 
pilot study performed by Naranjo et al. including Acanthamoeba keratitis (10 cases), 
Fusarium spp. (4 cases), Pseudomonas aeruginosa (2 cases), and Curvularia spp. (1 
case), evaluated the clinical outcomes of RB-PDAT. One patient had no microbio-
logical diagnosis [144]. Most individuals (14/18, 79%) were contact-lens wearers. 
Successful therapy, defined as avoiding therapeutic keratoplasty, was achieved in 
72% of the cases. Although adequately powered randomized controlled trials are 
required to ascertain the efficacy of RB-PDAT, preliminary results are promising.
9.7 Future drug-delivery systems
Despite the high efficacy and broad spectrum of the antimicrobials used in 
infectious keratitis, their insolubility in water, low precorneal residence time on the 
ocular surface, inadequate control of drug release and penetration, nasopharyngeal 
drainage, and toxicity hinders their performance [145]. To overcome such limita-
tions, recent developments on drug-delivery systems are emerging.
Chhonker et al. developed amphotericin-B-loaded lecithin/chitosan nanopar-
ticles with enhanced mucoadhesive properties for the prolonged ocular application 
[145]. The nanoparticles sized 161.9 to 230.5 nm improve drug bioavailability by 
approximately 2.04 fold and precorneal residence time by 3.36 fold in rabbit eyes 
[145]. Guo et al. developed self-assembled micelles of poly(ethylene glycol)-block-
poly(glycidyl methacrylate) (PEG-b-PGMA) to deliver natamycin [146]. The 
sustained drug release from micelles allows reducing the frequency of natamycin 
application from 8 to only 3 times per day in rabbits with fungal keratitis. The use of 
contact lenses as drug carriers or sustained-release deposits has also been evaluated 
to improve antimicrobial efficacy. Huang et al. developed a hybrid hydrogel-based 
contact lens, loaded with voriconazole, comprised of quaternized chitosan, gra-
phene oxide, and silver nanoparticles [147].
Another strategy employs carbon dots, which are small, highly fluorescent 
non-toxic element nanoparticles that measure less than 10 nm and are con-
sidered to replace metal-based quantum dots [148]. Zhao et al. demonstrated 
that nitrogen-doped carbon quantum dots sized 2–5 nm can destroy the cell 
structure of Staphylococcus aureus and methicillin-resistant Staphylococcus aureus 
(MRSA) [149].
There is a paucity of studies evaluating the efficacy of drug-delivery mecha-
nisms to manage infectious keratitis in humans. Such mechanisms may enhance 
drug penetration, better compliance, and reduced toxicity, thus improving patient 
outcomes.
9.8 Surgical procedures
Surgical management must be considered to maintain the globe integrity in 
patients with unresponsive keratitis associated with severe stromal melt with 
impending perforation risk. Zhong et al. demonstrated that full-thickness con-
junctival flap covering surgery with amniotic membrane transplantation might 
represent a viable option to save the eyeball for eyes with severe fungal keratitis 
without corneal perforation [150]. In their series, most eyes (15/17, 88%) achieved 
complete conjunctival re-epithelization. Seven of them achieved a mean best-
corrected visual acuity of ~20/100, remaining disease-free at least one month after 
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sclerokeratoplasty [150]. However, melting of the conjunctival flap, with subse-
quent endophthalmitis requiring evisceration, occurred in two eyes.
Therapeutic keratoplasty (TKP) should be reserved for patients who are not 
candidates for other therapies, and if possible, after quiescent infection [151]. 
In Acanthamoeba keratitis, TKP is recommended in cases of corneal perforation 
unresponsive to repeat gluing, severe corneal abscess, or significant cataract [113]. 
Because of the risk of rejection with large grafts in Acanthamoeba keratitis, corneal 
grafts must be kept to the minimum size required [113]. In cases of fungal keratitis, 
Selver et al. demonstrated that smaller grafts (< 8 mm) were associated with lower 
rejection rates, but higher recurrence rates possibly related to incomplete removal 
of infected tissue [151, 152].
10. Conclusions
Despite significant technological development in contact lens materials resulting 
in remarkable improvement in safety and comfort, microbial keratitis continues 
to be a severe sight-threatening complication in contact lens wearers. Overnight 
extended contact lens wear and deficient lenses and case hygiene continue to be 
the primary risk factors for CLAIK worldwide; hence improvement in contact lens 
hygiene, education, and handling is necessary to reduce this potential complication.
The clinician must be able to promptly recognize the condition and identify the 
causative microorganism through corneal scraping, smear, and culture in case of 
severe keratitis, and treat the disease according to the suspected etiological agent; 
Empirical treatment must be initiated in every case and modified according to the 
clinical response and microbiology laboratory results.
Appendix
Fortified topical antibiotic formulations and mode of preparation
Tobramycin 14 mg/mL or gentamicin 14 mg/mL
1. Withdraw 2 mL of either drug from an injectable vial (40 mg/mL).
2. Add 2 mL to an ophthalmic solution (5 mg) of either drug to give a 14 mg/mL solution.
3. Refrigerate and shake prior to instillation.
Cefazolin 50 mg/mL or ceftazidime 50 mg/mL
1. Add 9.3 mL of lubricant eyedrops to a vial of either drug, 1 g (powder for injection).
2. Dissolve. Take 5 mL and add it to 5 mL of lubricant eyedrops.
3. Refrigerate and shake prior to instillation.
Amikacin 10–40 mg/mL
1. Dilute intravenous formulation (80 mg/2 mL ampules) with lubricant eyedrops or 0.9% sodium 
chloride for injection USP to the desired concentration.
2. Refrigerate and shake prior to instillation.
Vancomycin 15 mg/mL, 25 mg/mL, or 50 mg/mL
1. Add either 33 mL, 20 mL, or 10 mL of 0.9% sodium chloride for injection USP, or artificial tears, to 
a vial of 500 mg of vancomycin to produce a solution of 15, 25, or 50 mg/mL, respectively.
2. Refrigerate and shake prior to instillation.
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Linezolid 2 mg/mL (for methicillin-resistant Staphylococcus aureus)
1. May be used directly from parenteral linezolid intravenous infusion available as 200 mg/100 mL.
Colistin 0.19% (for multiple drug-resistant Pseudomonas aeruginosa)
1. Add 1 million UI / 75 mg of parenteral colistimethate sodium powder to 10 ml of distilled water to 
obtain 7.5 mg/mL.
2. Withdraw 1 mL of the above solution and add to 3 mL of distilled water to obtain a 0.19% con-
centration
Trimethoprim (16 mg/mL) - sulfamethoxazole (80 mg/mL)
1. Commercial intravenous preparation may be used as topical solution without preparation.
Imipenem – cilastin (1%)
1. Add 10 mL of sterile water to parenteral imipenem (500 mg) – cilastin (500 mg) to create a 50 mg/
mL solution.
2. Withdraw 1 mL of the above solution and add 4 mL of sterile water to make topical 1% imipenem to 
obtain 1 mg/mL
3. Storage in amber-colored bottles
Data retrieved from [153].
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